AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Biotage

Legal Proceedings Report Mar 16, 2011

2894_rns_2011-03-16_a1c07177-b503-493c-9b9d-0379158fdf44.pdf

Legal Proceedings Report

Open in Viewer

Opens in native device viewer

Press release Biotage AB

Contact: SE-753 18 Uppsala Torben Jörgensen, President and CEO Tel+46 18 56 59 00 Tel: +46 707 49 05 84, [email protected] www.biotage.com

Uppsala March 16, 2011

Kungsgatan 76

Following Biotage's request for re-examination US Patent and Trademark Office has rejected all claims in US patent 7,381,327

A lawsuit was filed against Biotage by Scientific Plastic Products, Inc. concerning alleged infringement of the US patents no 7,138,061, 7,381,327 and 7,410,571.

Biotage then filed an application to the US Patent and Trademark Office applying for re-examination of all patent claims in the three patents mentioned above. At the same time Biotage submitted a request to stay the lawsuit in the district court pending the outcome of the re-examination proceedings. The court approved Biotage's request and declared the district court lawsuit stayed until resolution of the reexamination proceedings.

The US Patent and Trademark Office have now declared all claims of US patent 7,381,327 rejected. It is possible to file a notice of appeal. Decisions are expected concerning the two other patents later this year.

"Our initial analysis indicated that we have a strong position and that the plaintiff did not have good cause for the alleged patent infringement. The decision of the US Patent and Trademark Office confirms our assessment of the legal situation.", says Torben Jørgensen, CEO, Biotage AB.

The information in this press release is of the kind that Biotage AB (publ) may be required to make public according to the Securities Market Act and/or Financial Instruments Trading Act. The information was released for publication at 1pm on March 16, 2011.

About Biotage:

Biotage offers solutions, knowledge and experience in the areas of analytical chemistry and medicinal chemistry. The customers include the world's largest pharmaceutical and biotech companies, and leading academic institutes. The company is headquartered in Uppsala and has subsidiaries in the US, UK and Japan. Biotage has 272 employees and had sales of 428.9 MSEK in 2010. Biotage is listed on the NASDAQ OMX Nordic Stockholm stock exchange. Website:www.biotage.com

Talk to a Data Expert

Have a question? We'll get back to you promptly.